WebMar 6, 2024 · Half Year Accounts. 1mb. 15 February 2024. Response to ASX Query. 322kb. 13 February 2024. Opthea Ph2b Trial Results with OPT-302 published in Journal. 106kb. 9 February 2024. WebApr 12, 2024 · Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. About the company Rewards Trading at 90.9% below our estimate of its fair value Revenue is forecast to grow 85.83% per year Risk Analysis Makes less than USD$1m in revenue ($243K)
How DFIN helped dual-listed Opthea Limited optimize their …
Cooley previously advised Opthea on its $128 million initial public offering, which at the time marked the largest IPO conducted by a development-stage Australian life sciences company and the largest Australian biotech capital raise in a secondary Nasdaq IPO. WebApr 12, 2024 · Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. About the company OPT fundamental analysis Rewards Trading at 98% below our estimate of its fair value Revenue is forecast to grow 60.07% per year Risk Analysis Makes less than USD$1m in revenue … lake of the woods condos
Opthea’s Activity Leads to IPO - Ophthalmology Innovation Source
WebNov 3, 2024 · Opthea’s Nadsaq debut marks the largest IPO conducted by a development-stage Australian life sciences company, as well as the largest Australian biotech capital … WebSep 24, 2024 · O pthea, an Austrialian Phase 3 biotech developing therapies for wet AMD, filed on Thursday with the SEC to raise up to $150 million in an initial public offering. The South Yarra, Australia-based... WebOct 16, 2024 · Opthea plans to list on the Nasdaq under the symbol OPT. Citi and SVB Leerink acted as joint bookrunners on the deal. The article Australian retinal disease … lake of the woods contractors